Previous 10 | Next 10 |
Selected Recent Highlights: FDA approval of IHEEZO™ for ocular surface anesthesia Launch of Fortisite™, fortified antibiotics Launch of atropine.com™ compounded atropine portal Revenues of $22.8 million, up 22% over $18.7 million for the prior ...
Summary Harrow Health, Inc. is a well-managed ophthalmic medicines business. The company has remained profitable for a number of years. Harrow Health expects to double revenues in 2-3 years. For further details see: Harrow Health: Profitable Ophthalmi...
Announces Nationwide Availability of Compounded Atropine Formulations Harrow (Nasdaq: HROW), an eyecare pharmaceutical company exclusively focused on the discovery, development, and commercialization of innovative ophthalmic therapies, today announced the launch of atropin...
Harrow (Nasdaq: HROW), an eyecare pharmaceutical company exclusively focused on the discovery, development, and commercialization of innovative ophthalmic therapies, today announced that it will release its financial results for the third quarter ended September 30, 2022, on Monday, Nov...
Top-Line Results Expected by Year-End Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing novel approaches for procedural sedation and analgesia, today announced the dosing of the last patient in its Phase 2 pivotal efficacy and safety study for it...
Harrow ( NASDAQ: HROW ) said Wednesday it sold its non‑ophthalmic compounding business to Innovation Compounding Pharmacy, an affiliate of Revelation Pharma. Terms were not disclosed. The sale includes formulations, customer accounts and other related assets. ...
Harrow (Nasdaq: HROW), an eyecare pharmaceutical company exclusively focused on the discovery, development, and commercialization of innovative ophthalmic therapies, today announced the sale of its non‑ophthalmic compounding business to Innovation Compounding Pharmacy, LLC, an af...
Harrow Health, Inc. ( NASDAQ: HROW ), a healthcare company focused on eye disorders, gained ~15% Thursday after its San Diego-based subsidiary ImprimisRx announced the availability of Fortisite, a topical antibiotic formulation consisting of Tobramycin and Vancomycin. ...
ImprimisRx, America’s #1 Ophthalmic Pharmacy™, today announced the availability of Fortisite™, which includes a patent-pending compounded combination of Tobramycin 1.5% and Vancomycin 5%. Compounded topical antibiotic formulations may be appropriate to prescribe...
Micro-cap eyecare pharmaceutical company Harrow Health ( NASDAQ: HROW ) and Swiss injectable medicines firm Sintetica on Tuesday said the U.S. FDA had approved their gel for anesthesia of the surface of the eye. Shares of HROW jumped 27.3% to $9.69 in afternoon trading...
News, Short Squeeze, Breakout and More Instantly...
Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that its management team would attend the 2024 American Society of Retina Specialists (ASRS) Annual Meeting, taking place in Stockholm, Sweden, from July 17-20, 2024. The ASRS Annual Meeting brings tog...
Contract Enhances Purchasing Power for 340B Prime Vendor Program (PVP) Participants; Aligns with Harrow’s Mission to Make Its Products Accessible and Affordable Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that as of July 1, 2024, ...